Liposomal Doxorubicin
Treatment for Ovarian Cancer
Typical Dosage: 50 mg/m2 IV q4w
Effectiveness
60%
Safety Score
32%
Clinical Trials
260
Participants
7.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
32
DangerousModerateSafe
Treatment Details
Dosage Range
50 mg/m2 IV q4w
Time to Effect
1-2 months
Treatment Duration
3-6 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
12(Treat 12 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$9,000
Monitoring:$7,000
Side Effect Mgmt:$5,000
Total Annual:$21,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$60,000
Cost per Remission
$262,500
Liposomal Doxorubicin Outcomes
for Ovarian Cancer
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+35%
Remission Rate
+8%
Common Side Effects
Hand-Foot Syndrome
+45%
Myelosuppression (Neutropenia)
+35%
Nausea/Vomiting
+25%
Stomatitis/Mucositis
+25%
Alopecia
+15%
Active Clinical Trials
1 active trial recruiting for Liposomal Doxorubicin in Ovarian Cancer
Combination Therapy for Recurrent Ovarian Cancer
NCT05610735RECRUITINGPHASE1, PHASE2
72 participants
INTERVENTIONAL
Louisville, United States
Started: Sep 25, 2024
Completed Clinical Trials
11 completed trials for Liposomal Doxorubicin in Ovarian Cancer
DOXIL for Consolidation Therapy in Ovarian Cancer.
NCT00248248COMPLETEDPHASE2
45 participants
INTERVENTIONAL
Atlanta, United States
Started: Oct 1, 2005
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
NCT00659178COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Stanford, United States +2 more
Started: Jun 18, 2008
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
NCT00913835COMPLETEDPHASE2
125 participants
INTERVENTIONAL
Joliet, United States +5 more
Started: Jun 1, 2009
A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00727961COMPLETEDPHASE4
58 participants
INTERVENTIONAL
Started: Nov 9, 2004
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
NCT02394015COMPLETED
90 participants
OBSERVATIONAL
Started: May 6, 2013
Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type
NCT00861120COMPLETEDPHASE2
33 participants
INTERVENTIONAL
Innsbruck, Austria +5 more
Started: Apr 1, 2009
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
NCT02751918COMPLETEDPHASE1
65 participants
INTERVENTIONAL
Aurora, United States +8 more
Started: Jun 8, 2016
A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)
NCT00780039COMPLETEDPHASE2
58 participants
INTERVENTIONAL
Started: Oct 1, 2003
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
NCT00182767COMPLETEDPHASE1, PHASE2
45 participants
INTERVENTIONAL
Farmington, United States +4 more
Started: Jan 1, 2006
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
NCT00628251COMPLETEDPHASE2
97 participants
INTERVENTIONAL
Los Angeles, United States +23 more
Started: Jul 30, 2008
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
NCT01113957COMPLETEDPHASE2
168 participants
INTERVENTIONAL
Duarte, United States +31 more
Started: Mar 1, 2010
Showing 20 of 276 total trials